Form D · Pharmaceuticals

T3D Therapeutics, Inc.

Research Triangle Park, NC · CIK 0001579600

Offering snapshot reported Sep 6, 2022 · SEC filing

Reported sold
$6M
Offering amount: $7.5M
Investors reported
23
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 26, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 6, 2022Initial$6,002,712No comparison23SEC filing
Nov 1, 2019Initial$15,000,000No comparison1SEC filing
Mar 12, 2018Initial$6,000,000No comparison1SEC filing
Jan 12, 2018Initial$711,270No comparison30SEC filing
Mar 14, 2016Amendment$1,210,206$1,095,204vs Mar 13, 201518SEC filing
Mar 13, 2015Initial$115,002No comparison2SEC filing
Mar 14, 2014Initial$660,997No comparison9SEC filing
Aug 5, 2013Initial$437,000No comparison17SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-457972

Source: Form D, filed Sep 6, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Barry Buzogany Director
John Didsbury Director, Executive, Promoter
John Golden Director
David Keim Director
Charles Lineberry Director
Tom Mendell Director
Donald Parker Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
68 T.W. Alexander Drive
Research Triangle Park, NC, 27709